<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">Typically, baseline CD4+ cell counts would be measured immediately after patients are newly diagnosed as HIV positive. Since 2014, the national criteria for starting ART are (1) CD4+ cell count &lt; 500 cells/μl, (2) AIDS progression to III/IV stage, or (3) willingness to receive ART, regardless of CD4+ cell counts or AIDS progression. In 2016, these guidelines were changed to offer free ART to all HIV-infected patients, regardless of CD4+ cell counts, with the provision of informed consent. According to the WHO guidelines, the current first-line combined ART regimens in China include tenofovir (TDF) or zidovudine (AZT) with lamivudine (3TC) and efavirenz or nevirapine. The second-line ART regimens include TDF or AZT with 3TC and lopinavir-ritonavir
 <sup>
  <xref ref-type="bibr" rid="CR43">43</xref>
 </sup>.
</p>
